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Leukemia stem cells (LSCs) are a rare subpopulation
of abnormal hematopoietic stem cells (HSCs) that
propagates leukemia and are responsible for the
high frequency of relapse in therapies. Detailed in-
sights into LSCs’ survival will facilitate the identifica-
tion of targets for therapeutic approaches. Here, we
develop an inhibitor, LYZ-81, which targets ORP4L
with high affinity and specificity and selectively erad-
icatesLCSs in vitroand in vivo. ORP4L is expressed in
LSCs but not in normal HSCs and is essential for LSC
bioenergetics and survival. It extracts PIP2 from
the plasma membrane and presents it to PLCb3,
enabling IP3generationandsubsequentCa
2+-depen-
dent bioenergetics. LYZ-81 binds ORP4L competi-
tively with PIP2 and blocks PIP2 hydrolysis, resulting
in defective Ca2+ signaling. The results provide evi-
dence that LSCs can be eradicated through the inhi-
bition of ORP4L by LYZ-81, which may serve as a
starting point of drug development for the elimination
of LSCs to eventually cure leukemia.
INTRODUCTION
Leukemia stem cells (LSCs) are a rare subpopulation of
abnormal hematopoietic stem cells that propagates leukemia
(Elert, 2013; Lapidot et al., 1994) and is responsible for the
high frequency of relapse that is characteristic of current leuke-
mia therapies (Schepers et al., 2015). Initially, LSCs were identi-
fied as having the CD34+CD38 phenotype, similar to normal2166 Cell Reports 26, 2166–2177, February 19, 2019 ª 2019 The Aut
This is an open access article under the CC BY-NC-ND license (http://hematopoietic stem cells (HSCs) (Bonnet and Dick, 1997). Leu-
kemia initiating and maintaining capacity has been described
in other immunophenotypically defined acute myeloid leukemia
(AML) subpopulations (Eppert et al., 2011). However, immature
CD34+CD38 cells remain the best-characterized and most
potent population initiating leukemia in various xenograft mouse
models and retransplantation experiments (Bonnet and Dick,
1997; Eppert et al., 2011; Ishikawa et al., 2007; Lechman et al.,
2016; Reya et al., 2001; Saito et al., 2010). LSCs share many
properties, such as self-renewal, differentiation potential, and
quiescent cell-cycle status, with HSCs (Clevers, 2011; Huntly
and Gilliland, 2005). The tendency to remain quiescent renders
LSCs resistant to conventional chemotherapeutic agents and
radiation, which predominantly target proliferating cells (Huntly
and Gilliland, 2005; Tallman et al., 2005). Hence, failure to erad-
icate quiescent LSCs may result in reinitiating the malignancy
after a period of latency. It is therefore crucial to develop thera-
peutic approaches that target quiescent LSCs.
The second messenger inositol-1,4,5-trisphosphate (IP3) is
generated by the hydrolysis of phosphatidylinositol-4,5-
bisphosphate (PIP2) located in the plasma membrane (PM) by
phospholipase C (PLC) (Rhee et al., 1989). When a ligand binds
to a receptor coupled to a Gq heterotrimeric G protein, the
a-subunit of Gq induces the activity of PLCb, resulting in the
cleavage of PIP2 into IP3 and diacylglycerol (DAG) (Qin et al.,
2011). The binding of IP3 to receptors in the endoplasmic reticu-
lum (ER) results in Ca2+ egress and mediates a range of cellular
responses (Berridge et al., 2000).
Oxysterol-binding protein (OSBP) and its relatives (ORPs)
have emerged as mediators of the interorganelle transfer
of cholesterol or phospholipids in exchange for phosphatidylino-
sitol-4-phosphate (PI(4)P) (Mesmin et al., 2013; Tong et al.,
2013; Yang, 2006). OSBP mediates sterol and PI(4)P exchangehor(s).
creativecommons.org/licenses/by-nc-nd/4.0/).
between the ER and the Golgi (Mesmin et al., 2013), while
ORP5/8 exchange phosphatidylserine (PS) for PI(4)P at ER-PM
junctions (Chung et al., 2015; Sohn et al., 2018). An essential
role of ORP5/8 as a transporter for PIP2 rather than PI(4)P has
recently been explored (Ghai et al., 2017), and ORP2 acts as a
selective transporter of cholesterol and PIP2 at the PM (Wang
et al., 2018). Earlier studies suggested that ORP4L may be aber-
rantly induced in distinct malignant cell types (Charman et al.,
2014; Fournier et al., 1999; Henriques Silva et al., 2003). Our
recent work showed that ORP4L is expressed in T cell acute
lymphoblastic leukemia (T-ALL) cells but not normal T cells and
is essential for cell survival (Zhong et al., 2016b). ORP4L controls
G protein-coupled IP3 signaling in T-ALL cells and plays an oblig-
atory role in efficient ATP production via oxidative phosphoryla-
tion. However, the mechanism through which ORP4L regulates
PLCb3 catalysis is poorly understood. Given the critical role of
ORPs in phosphoinositide metabolism and transport, under-
standing how ORP4L facilitates IP3 generation by PLCb3 is a
fundamental and clinically significant question.
In this study, we report that ORP4L executes an essential
function in the survival of LSCs: it extracts PIP2 from the PM
and presents it to PLCb3 for hydrolysis, inaugurating the concept
that a PIP2-presenting cofactor is required for PLC catalysis.
Moreover, we explore a compound, LYZ-81, that blocks
ORP4L function to eradicate leukemia.
RESULTS
ORP4L Is Selectively Expressed in LSCs, but Not HSCs,
and Is Essential for the Survival of LSCs
Our previous study showed that the abnormal expression of
ORP4L is essential for T-ALL cell survival (Zhong et al., 2016b).
The crucial role of LSCs that propagate leukemia (Lapidot
et al., 1994) prompted us to investigate the role of ORP4L in
this cell type. LSCs from AML constitute the best-characterized
LSC subpopulation (Schepers et al., 2015). We isolated
LSCs from the bone marrow of AML patients by using the
CD34+CD38 markers and validated the stem cell status of the
isolated cells (see Method Details). High levels of ORP4L
mRNA and protein were detected in all CD34+CD38-LSCs
specimens, whereas they were absent in HSCs (Figures 1A
and 1B).
To investigate a putative role of ORP4L in the LSCs, we carried
out knockdown experiments demonstrating that ORP4L deple-
tion reduced the colony-forming capacity of the LSCs (Fig-
ure 1C), accelerated the death of LSCs (Figure 1D), and signifi-
cantly reduced the in vivo engraftment of LSCs in NOD/SCID
mice (Figure 1E). To control for possible off-target effects, we
carried out a number of RNA interference experiments by using
another independent ORP4L small hairpin RNA (shRNA), with
similar results (Figures S1A and S1B). The results suggested
that ORP4L is expressed in LSCs and is required for the survival
of these cells.
LYZ-81 Is a Specific Inhibitor of ORP4L
The role of ORP4L in LSCs survival prompted us to investigate
the possibility of targeting ORP4L for leukemia therapy. OSW-1
is an anti-proliferative compound that targets ORP4L andOSBP (Burgett et al., 2011). ORP4L shows a restricted tissue
expression pattern, whereas OSBP is ubiquitous (Udagawa
et al., 2014). We hypothesized that the toxicity of OSW-1 toward
normal cells may be due to its affinity for OSBP; thus, a com-
pound sparing OSBP could be more selective toward cancer
cells. To this end, we synthesized OSW-1 analogs, as described
(Zheng et al., 2010), and uncovered a compound called LYZ-81
(Figure 2A) that exhibited a drastically more pronounced differ-
ence in the half-maximal inhibitory concentration (IC50) toward
LSCs versus HSCs (IC50 = 3.27 nM in LSCs versus IC50 =
1.29 mM in HSCs) than OSW-1 (Figures S2A and S2B). Surface
plasmon resonance (SPR) assays demonstrated that LYZ-81
binds ORP4L (Kd = 1.05 ± 0.24 nM; Figure 2B). Homology
modeling and molecular docking studies suggested that LYZ-
81 binds to ORP4L via hydrogen bonding, forming a stable
complex through four residues—Met527, Arg594, Asn600, and
Lys681—within the oxysterol-binding domain (ORD) of ORP4L
(Figure 2C). To experimentally validate the in silico docking anal-
ysis, we constructed an ORP4L mutant, designated ORP4L M4
(Met527Gly, Arg594Gly, Asn600Gly, and Lys681Gly). SPR ana-
lyses demonstrated that ORP4L M4 shows a very low affinity
for LYZ-81 (Figure S2C), indicating a key role of the four residues
in the binding of the compound to ORP4L. This binding mode of
LYZ-81 to ORP4L was further supported by experiments in
which overexpression of wild-type ORP4L but not ORP4L M4
partly rescued LSCs from death induced by LYZ-81 (Figure 2D).
LYZ-81 showed a dose-dependent cytotoxicity toward LSCs at
1–10 nMconcentrations, while there was no effect on HSCs even
at the highest dose (Figures 2E and 2F; Table S1), as evidenced
by the induction of cell death and inhibition serials of colony
formation. Together, the data indicate that LYZ-81 eradicates
LSCs but not HSCs in vitro.
To address the specificity of LYZ-81 binding to ORP4L, we
used SPR assays to determine the binding affinity of OSW-1
and LYZ-81 to ORP4L and OSBP. OSW-1 displays a similar,
nanomole binding affinity for these two proteins (Kd (ORP4L) =
0.85 ± 0.17 nM, Kd (OSBP) = 1.49 ± 0.26 nM) (Figures S2D and
S2E). By contrast, LYZ-81 binds ORP4L with markedly greater
affinity than OSBP (Kd (ORP4L) = 1.05 ± 0.24 nM, Kd (OSBP) = 5.9
± 1.86 mM) (Figures 2B and S2F), revealing a strong preference
of LYZ-81 for ORP4L. OSW-1 was shown to promote OSBP
degradation via a proteasome-dependent pathway (Burgett
et al., 2011). To determine whether OSW-1 or LYZ-81 also
causes a reduction in the amount of ORP4L, we assessed
ORP4L protein levels in compound-treated LSCs by western
blotting. Treatment with either compound did not affect ORP4L
protein levels (Figure S2G). While OSW-1 induced a dramatic
reduction of OSBP in LSCs, no such effect was seen in LYZ-81
treated cells (Figure S2G), adding evidence for the specificity
of this compound for ORP4L. Overexpression of either ORP4L
or OSBP protected LSCs against cell death induced by
OSW-1. However, only ORP4L but not OSBP protected the cells
against the cytotoxicity of LYZ-81 (Figure S2H). LYZ-81 exe-
cutes cytotoxic activity toward LSCs via targeting ORP4L, while
sparing OSBP.
To evaluate the cytotoxicity of OSW-1 and LYZ-81 in vivo,
OSW-1 (5.8 mg/kg/day, intravenously [i.v.]) or LYZ-81 (5.8 mg/
kg/day, i.v.) (Tamura et al., 1997) were injected into mice forCell Reports 26, 2166–2177, February 19, 2019 2167
Figure 1. ORP4L Expression in LSCs Is Essential for LSC Survival
(A and B) qPCR (A) and western blot (B) analysis of ORP4L expression in HSCs (n = 6) and LSCs from subjects with AML (n = 45 for qPCR, n = 16 for western blot).
Relative gene expression is presented as log(2DDCt). The western blot is representative of 3 independent experiments with similar results.
(C) The in vitro colony-forming ability of LSCs (n = 3, AML 1, 2, 3 specimens) with ORP4L knockdown. After infection with non-targeting shRNA (shNT) or shORP4L
lentivirus for 48 h, the infected cells with GFP were sorted by flow cytometer and plated in Methocult GF and cultured for 14 days. Representative colony
microscopy images of the specimens are shown. Mean ± SD values from an experiment performed in triplicate with each specimen are plotted. **p < 0.01,
Student’s t test.
(D) Cell death analysis in LSCs (n = 10) with ORP4L knockdown. Cells were infected with shNT or shORP4L lentivirus for 120 h before analysis. Representative
images of cell death analysis by fluorescence-activated cell sorting (FACS) are shown. The percentage of cell death from independent AML specimens are
shown. **p < 0.01, Student’s t test.
(E) Percentage of engraftment of leukemia cells (AML 2 specimen) in the bonemarrow of NOD/SCIDmice (n = 8 for shNT, and n = 6 for shORP4L). Representative
images of FACS analysis from one of the mice are shown. The engraftment percentages of leukemia cells from each mouse are plotted. ***p < 0.001, Student’s
t test.7 weeks. Histological analysis revealed that LYZ-81 treatment
did not alter the gross histology of spleen, bone marrow, heart,
brain, kidney, or muscle of the animals (Figure S2I). However,
the spleen and bone marrow of OSW-1 treated mice displayed
abnormal cell morphology, smaller cell size, and narrowing of
intercellular spaces (Figure 2G). These observations are consis-
tent with the view that LYZ-81 is less toxic to normal cells than is
OSW-1.2168 Cell Reports 26, 2166–2177, February 19, 2019LYZ-81 Preferentially Eradicates LSCs Ex Vivo and
In Vivo
To assess the capacity of LYZ-81 treatment ex vivo to reduce
LSCs engraftment, we pre-treated AML-CD34+ or umbilical
cord (UBC)-CD34+ cells with LYZ-81 and transplanted them
into sublethally irradiated NOD/SCID mice (Figure S3A). Ex vivo
pre-treatment of AML-CD34+ cells with LYZ-81 significantly
reduced the engrafted LSCs inmousebonemarrow (Figure S3B).
Figure 2. LYZ-81 Selectively Targets ORP4L
(A) The chemical structure of OSW-1 and LYZ-81.
(B) Binding of LYZ-81 to ORP4L in an SPR assay.
(C) Surface representation showing the binding of
LYZ-81 to modeled ORP4L.
(D) LSCs (AML 12 specimens) were transfected
with empty vector, wild-type ORP4L, or LYZ-81
binding site mutant ORP4L (ORP4L M4) cDNA for
24 h, incubated with or without 5 nM LYZ-81 for
16 h, and evaluated for cell death. Representative
images of flow cytometry are shown.
(E) In vitro cell death analyses of HSCs (n = 4) and
LSCs (n = 13, AML-1, -2, -3, -4, -5, -6, -7, -8, -9,
-11, -12, -13, and -14 specimens) treated with
increasing concentrations of LYZ-81 are shown.
Details of each AML specimen are shown in
Table S1.
(F) The in vitro colony-forming ability of LSCs in the
first and second replanting (n = 5, AML-1, -2, -5,
-6, and -10 specimens) and HSCs (n = 4) as
examined in the absence or presence of 5 nM
LYZ-81. Data are means ± SDs of at least three
independent experiments. **p < 0.01, ***p < 0.001,
NS, not significant, Student’s t test.
(G) H&E stained tissue sections of mice treated
with LYZ-81 or OSW-1. The mice were sacrificed
after drug treatments at 5.8 mg/kg/day, intraperi-
toneally (i.p.) for 7 weeks. Similar results were
obtained for five mice in each group. Images from
one representative mouse per group are shown.
Scale bars, 100 mm.In contrast, engraftment of HSCs was not affected by LYZ-81
treatment (Figure S3C). The decreased engraftment of LYZ-
81-treated LSCs was partly rescued by the overexpression of
ORP4L before the treatment (Figure S3D), which is consistent
with the view that LYZ-81 eliminates LSCs via targeting ORP4L.
To test the therapeutic potential of LYZ-81, we treated NOD/
SCID mice engrafted with AML-CD34+ or UBC-CD34+ cells with
LYZ-81 for 7 weeks (Figure 3A). The engrafted leukemia cells
and LSCs were determined before and after 1, 2, 4, 5, and
7 weeks of treatment by analyzing peripheral blood leukocytes.
Notably, increased numbers of hCD45+ cells and LSCs were
found in mice injected with PBS in a series of treatment time
courses (Figure S4A), while remarkable reductions in hCD45+
cells and LSCs were evident after 4 and 5 weeks of LYZ-81 treat-
ment. No detectable hCD45+ cells or LSCs were found in the pe-
ripheral blood of the animals after LYZ-81 treatment for 7 weeks
(Figure S4A). LYZ-81 did not exert a significant reduction in
hCD45+ cells or HSCs in mice engrafted with HSCs (Figure S4B).Cell RepoAfter 7 weeks of therapy, we analyzed
the bone marrow of the mice. The LYZ-
81 treatment fully eliminated leukemia
cells and LSCs from the bone marrow
(Figures 3B and 3C). However, LYZ-81
did not reduce the engraftment of HSCs
(Figure 3D). Staining of spleen and
bone marrow sections with anti-hCD34
supported the notion that LYZ-81 can
completely eradicate LSCs in vivo(Figure 3E). Furthermore, LYZ-81 therapy significantly delayed
tumor-related death of the animals (Figure 3F). Thus, pharmaco-
logic inhibition of ORP4L by LYZ-81 markedly and selectively
eradicates LSCs both in vitro and in vivo.
ORP4L Facilitates PIP2 Clearance in the PM
Similar to Jurkat T cells, ORP4L interacts with Gaq/11 and PLCb3
upon stromal cell-derived factor 1a (SDF-1a) (a cytokine binding
G protein-coupled receptor CXCR4 [Murdoch, 2000]) stimulation
in LSCs (Figures S5A and S5B). Knockdown of PLCb3 signifi-
cantly reduced IP3 production in LSCs (Figure S5C), indicating
that the PLCb3 isoform plays a dominant role in IP3 production
in these cells. ORP4L depletion significantly reduced the sponta-
neous cytosolic [Ca2+]c and mitochondrial [Ca
2+]m oscillations
(Figure S5D) that are associated with the inactivation of
pyruvate dehydrogenase (PDH; Figure S5E), reduction of oxygen
consumption rate (OCR), and ATP production (Figure S5F).
Furthermore, ORP4L knockdown reduced AMP kinase (AMPK)rts 26, 2166–2177, February 19, 2019 2169
Figure 3. LYZ-81 Eradicates LSCs In Vivo
(A) Overview of the experimental design for LYZ-81 therapy after xenotransplantation of LSCs and HSCs into NOD/SCID mice.
(B) Engraftment of human leukemia cells (AML-1, AML-5, and AML-6 specimens) in the bone marrow of NOD/SCID mice after treatment with vehicle control or
LYZ-81 (5.8 mg/kg/day, i.v.) for 7 weeks. The percentage engraftment of leukemia cells in each mouse is plotted. ***p < 0.001, Student’s t test.
(C) Representative images of flow cytometry from one of the mice are shown.
(D) Engraftment of human normal human cells in the bone marrow of NOD/SCID mice after treatment with vehicle control or LYZ-81 (5.8 mg/kg/day, i.v.) for
7 weeks. The percentage engraftment of HSCs in each mouse is plotted. NS, not significant, Student’s t test.
(E) Staining of hCD34 antibody in spleen and bone marrow from mice grafted with untreated or treated AML specimens. Scale bars, 10 mm. Similar results were
obtained for the five mice of each group.
(F) The survival of the mice (n = 10) was compared by Kaplan-Meier analysis, with statistical significance determined by log-rank test. ***p < 0.001.activation and induced autophagy (Figure S5G). To strengthen
the link betweenORP4L, Ca2+ signaling andmitochondrial meta-
bolism, we used the mitochondrial calcium uniporter (MCU)
agonist kaempferol (Montero et al., 2004), which abolished the
inactivation of PDH, the elevated autophagy, the reduced
OCR, and the dampened ATP production upon ORP4L knock-
down (Figure S5H). LSC death was rescued by the inhibitor of
autophagy, 3-methyladenine (Figure S5I), indicating that2170 Cell Reports 26, 2166–2177, February 19, 2019ORP4L knockdown induced LSC death via an autophagic
mechanism.
To identify the function of ORP4L in LSCs, we carried out the
following experiments in the CD34+CD38 KG1-a cell line that
meets the properties of stem cells (She et al., 2012). ORP4L is
highly expressed in CD34+CD38 KG1-a cells (Figure S6A),
and its knockdown (Figure S6B) induced cell death (Figure S6C).
Prompted by the functions of ORPs as lipid transporters and role
Figure 4. ORP4L Increases PIP2 Clearance at the PM
(A) Heatmap visualization of the significantly changed lipid species in the plasmamembrane (PM) of KG1-a cells with ORP4L knockdown. Cells were treated with
500 ng/mL of SDF-1a for 5 min before PM preparation.
(B and C) Kinetics of PM PIP2 decline upon treatment of KG1-a cells (B) or primary LSCs (C, AML-2 specimen) with 500 ng/mL of SDF-1a, upon ORP4L
knockdown or overexpression.
(D and E) Representative images of the kinetics of PIP2 clearance in the PM of KG1-a cells with 500 ng/mL of SDF-1a, upon ORP4L knockdown (D) or over-
expression (E). Data are means ± SDs of at least 30 cells observed.of ORP4L with IP3 production at the PM, we isolated PM from
control and ORP4L-deficient CD34+CD38 KG1-a cells. Global
lipidomics profiling revealed that phosphatidylinositols (PIs)
were significantly enriched, whereas the products of PLC,DAGs, were reduced upon the loss of ORP4L (Figure 4A), indi-
cating a function of ORP4L in the metabolism of PI at the PM.
We therefore measured the kinetics of PIP2 clearance in the
PM after ligand stimulation. The PM PIP2 levels declined steadilyCell Reports 26, 2166–2177, February 19, 2019 2171
Figure 5. ORP4L Extracts PIP2 from the PM
(A and B) RMSD curves of apo-ORP4L (A) and
ORP4L/PIP2 complex (B).
(C) The binding of PIP2 to modeled ORP4L by
molecular docking.
(D) The binding pocket of ORP4L aligned onto
apo-ORP4L. Magenta lines indicate movements
from apo-ORP4L to PIP2-bound ORP4L.
(E–H) Binding of PIP2 to full-length ORP4L (E),
ORP4L-ORD (F), ORP4L-PH (G), and PLCb3-PH
(H) in an SPR assay.
(I) Schematic of the PIP2 extraction experiments
(see Method Details).
(J) Dot-blot to determine the ability of inactivated
or activated (with GTPgS) PLCb3 to extract PIP2.
The PLCb3 activities are shown in Figure S6E.
After reaction, the PIP2 remaining in the PM were
analyzed.
(K) Dot-blot to determine the ability of ORP4L
and the indicated truncated ORP4L constructs to
extract PIP2.after SDF-1a stimulation of KG1-a cells, and ORP4L knockdown
reduced (Figures 4B and 4D; Video S1) while ORP4L overexpres-
sion accelerated the clearance of PIP2 (Figures 4B and 4E).
Similar effects of ORP4L manipulations on PIP2 clearance were
observed in primary LSCs upon SDF-1a stimulation (Figure 4C).
ORP4L Binds and Extracts PIP2 from the PM
To investigate whether ORP4L regulates PIP2 clearance at the
PM by a direct interaction with PIP2, the three-dimensional (3D)
structure of ORP4L-ORD was predicted through homology
modeling and subjected to 100-ns molecular dynamics simula-
tions with the head group of PIP2. According to root-mean-2172 Cell Reports 26, 2166–2177, February 19, 2019square deviation (RMSD) curves, the
pocket entrance (residues 520–540,
622–631, and 836–853) of apo-ORP4L
expanded during 30–60 ns and then
restored a closed conformation (Fig-
ure 5A; Video S2). However, as for
the ORP4L/PIP2 complex, the pocket
entrance expanded over time (Figure 5B;
Video S3). In the privileged conforma-
tion, PIP2 formed hydrogen bonds with
specific hydrophilic residues of ORP4L
(Arg537, Asn600, Ser650, Lys652,
Gln848, Arg849, and Arg852) at the
pocket entrance area (Figure 5C). Align-
ment of ORP4L/PIP2 with apo-ORP4L
revealed that the pocket entrance in
ORP4L/PIP2 expanded (magenta lines in
Figure 5D). Immunofluorescence staining
showed the co-localization of ORP4L and
PIP2 in KG1-a and LSCs (Figure S6D).
SPR assays further confirmed that the
full-length ORP4L (Figure 5E) and its
ORD (Figure 5F) but not its Pleckstrin
homology (PH) domain (Figure 5G) bind
PIP2. The ORD of ORP4L has higheraffinity for PIP2 than the PH domain of PLCb3 (Figure 5H), indi-
cating a preference of PIP2 for binding ORP4L.
Given the direct ORP4L/PIP2 interaction, we postulated that
ORP4L may extract PIP2 from the PM. After incubating PMs
with purified glutathione S-transferase (GST)-PLCb3 or GST-
ORP4L proteins, the PMs were collected and the PIP2 remaining
in themembranes was analyzed tomonitor the extraction capac-
ity of the proteins (Figure 5I). PLCb3 was activated by guanosine
triphosphate (GTP)gS (Figure S6E), as previously described
(Hepler et al., 1993). We found that PLCb3 (inactive or GTPgS-
bound active form) alone was unable to extract PIP2 (Figure 5J).
In contrast, incubation with ORP4L decreased the amount of
Figure 6. ORP4L Presents PIP2 to PLCb3 for
Catalysis
(A) Schematic presentation of the cell-free system
experiments (see Method Details).
(B) The amount of PIP2 (top) and DAG in the PM
and the IP3 released (bottom) after cell-free re-
constituted reactions in the presence of the indi-
cated recombinant proteins.
(C and D) Kinetics of PM PIP2 decline upon treat-
ment of KG1-a cells (C) and primary LSCs (D,
AML-2 specimen) with 500 ng/mL of SDF-1a upon
the indicated genetic manipulations.
(E and F) DAG (E) in the PM and the IP3 released (F)
in KG1-a cells and primary LSCs (AML-2, -6, and
-12 specimens) upon the indicated genetic ma-
nipulations. Cells were stimulated with 500 ng/mL
of SDF-1a for 3 min before analysis.
(G) SMD simulations for 2 ns demonstrating the
dissociation of IP3 from ORP4L. Data are means ±
SDs of at least three independent experiments.
*p < 0.05, **p < 0.01, Student’s t test.PIP2 in the PM fraction, with a concomitant increase in its amount
bound to the ORP4L (Figure 5K), demonstrating the extraction of
PIP2 from the PM by ORP4L. Furthermore, the ORD but not the
PH domain of ORP4L was crucial for its PIP2 extraction capacity
(Figure 5K).
ORP4L Presents PIP2 to PLCb3 for Hydrolysis
We next reconstituted a cell-free system to study the hydrolysis
of PIP2 in the presence or absence of ORP4L and PLCb3. To
exclude endogenous ORP4L, PMs were isolated from KG1-a
cells with 90% knockdown of ORP4L. After the reaction, pellets
containing the PM were analyzed for PIP2 and DAG and the su-
pernatants for IP3 (Figure 6A). PLCb3 alone did not induce the
loss of PIP2 or the production of second messengers DAG and
IP3. However, the combination of ORP4L and PLCb3 dramati-Cell Repocally decreased the PIP2 level and
concomitantly increased the production
of the second messengers. We next
generated ORP4L mutants deficient in
PIP2 binding (replaced Arg537, Asn600,
Ser650, Lys652, Gln848, Arg849, and
Arg852 by Gly, ORP4LDPIP2) and
PLCb3 binding (ORP4LDPLCb3) (Zhong
et al., 2016a). These two ORP4L mutants
abolished the effects of the protein on
PIP2, DAG, and IP3 (Figure 6B). In living
cells, ORP4L knockdown reduced the
clearance of PIP2 (Figures 6C and 6D,
left) and decreased the second messen-
gers (Figures 6E and 6F, left) in both
KG1-a and LSCs, while PLCb3 overex-
pression increased all of these parame-
ters, these effects being abolished upon
ORP4L knockdown (Figures 6C and 6D,
left; Figures 6E and 6F, left). Our recent
work showed that ORP4L is required for
PLCb3 translocation from the nucleusto the PM. In ORP4L knockdown cells, wild-type ORP4L and
ORP4LDPIP2 rescued the PLCb3 translocation, indicating that
abolishing PIP2 binding by ORP4L did not affect the role of
ORP4L in PLCb3 translocation. However, the ORP4LDPLCb3
mutant was unable do this (Figure S6F). Overexpression of
wild-type ORP4L but not the mutants increased the PIP2 clear-
ance (Figures 6C and 6D, right) and second messenger produc-
tion (Figures 6E and 6F, right). Although the ORP4LDPIP2 mutant
retained the PLCb3 translocation ability, the defect of PIP2
hydrolysis in ORP4LDPIP2 overexpressing cells indicated the
requirement of PIP2 extraction and presentation for this catal-
ysis. Of note, IP3 was released after PLC catalysis in our cell-
free system and in living cells. To address the dissociation of
IP3 from the binding pocket of ORP4L, 2-ns steered molecular
dynamics (SMD) were performed on the ORP4L/IP3 complexrts 26, 2166–2177, February 19, 2019 2173
Figure 7. LYZ-81 Inhibits PIP2 Hydrolysis by Targeting ORP4L
(A) Microscale thermophoresis analysis of PIP2 binding to ORP4L in the presence or absence of 5 nM LYZ-81.
(B) Dot-blot to determine the ability of ORP4L to extract PIP2 in the presence or absence of a series concentration of LYZ-81.
(C and D) The amount of PIP2 (C) andDAG (D) in the PMand the IP3 produced (D) after cell-free reconstituted reactions in the presence or absence of 5 nMLYZ-81.
(E) The amount of PIP2 (left) and DAG (center) in the PM and the IP3 production (right) in living LSCs (AML-2 specimen) with or without LYZ-81 pre-treatment (5 nM,
4 h). The cells were stimulated for 3 min with SDF-1a (500 ng/mL) before analysis.
(F) Spontaneous [Ca2+]c and [Ca
2+]m oscillations in control or ORP4L overexpressing LSCs (AML-6 specimen) with or without LYZ-81 pre-treatment (5 nM, 4 h).
(G)Westernblot analysis (left) of p-PDH,p-AMPK, andLC3 in control orORP4LoverexpressingLSCs (AML-3specimen)withorwithout LYZ-81 treatment (5 nM,4h).
OCR (center) and ATP (right) levels in control or ORP4L overexpressing LSCs (n = 3, AML-1, -3, and -6 specimens) with or without LYZ-81 treatment (5 nM, 4 h).
(H) Cell death analysis in control and LYZ-81 treated LSCs (5 nM, 16 h, n = 3, AML-1, -3, and -6 specimens) with or without the autophagy inhibitor 3-methyl-
adenine (3-MA) (5 mM, 16 h).
(I) Cell death analysis in control and LYZ-81 treated LSCs (5 nM, 16 h, n = 3, AML-1, -3, and -6 specimens) with or without ORP4L or ORP4LDPIP2 overexpression.
(J) Western blot analysis of p-PDH, p-AMPK, and LC3 in LSCs (AML-6 specimens) isolated from control or LYZ-81 treated mice. Data are means ± SDs of at least
three independent experiments. **p < 0.01, ***p < 0.001, Student’s t test.
2174 Cell Reports 26, 2166–2177, February 19, 2019
through 100-nsMD simulations. At the beginning, IP3 was bound
in the binding pocket of ORP4L at Arg 537, Lys 597, Asn 600,
Ser 650, Ser 651, Lys 652, Arg 849, and Arg 852. During the
2-ns SMD simulations, the hydrogen bonds were broken, and
IP3 eventually escaped from the binding pocket. Pulling IP3
outside the binding pocket of ORP4L was calculated to cost
17.85 ± 2.10 kcal/mol work (Figure 6G; Video S4).
LYZ-81 Blocks PIP2 Hydrolysis by Targeting ORP4L
We further investigated the detail mechanism of LYZ-81 cytotox-
icity. Microscale thermophoresis (MST) indicated that LYZ-81
competed with PIP2 for binding to ORP4L (Figure 7A). In the
cell-free reconstituted system, LYZ-81 inhibited the extraction
of PIP2 by ORP4L in a dose-dependent manner (Figure 7B)
and decreased PM PIP2 clearance and production of the second
messengers (Figures 7C and 7D). Similar to ORP4L knockdown,
LYZ-81 treatment increased in living LSCs the PM PIP2 levels
and reduced second messenger production; these effects
were partly rescued by ORP4L overexpression (Figure 7E).
Moreover, LYZ-81 treatment decreased the [Ca2+]c and
[Ca2+]m oscillations (Figure 7F), increased phospho (p)-PDH
and p-AMPK, and reduced OCR and ATP production in LSCs
(Figure 7G), while ORP4L overexpression consistently reversed
these effects. LYZ-81 treatment also induced the autophagic
death of the LSCs (Figure 7H). The full-length ORP4L but not
ORP4LDPIP2 rescued the cell death induced by LYZ-81 (Fig-
ure 7I), indicating that blocking PIP2 extraction and presentation
by ORP4L is the key mechanism underlying LYZ-81 cytotoxicity.
Furthermore, we isolated and analyzed the remaining human
LSCs from animals grafted with AML-6 (see Figure 3B). LYZ-81
treatment of the engrafted animals reduced the PDH activity
and increased the p-AMPK levels and autophagy in these cells
(Figure 7J), which is consistent with the view that LYZ-81 eradi-
cates LSCs via an autophagic pathway also in vivo.
DISCUSSION
In this study, we found that ORP4L inhibition selectively eradi-
cated LSCs in vitro and in vivo. ORP4L was found to be ex-
pressed selectively in LSCs, but not in normal HSCs, and to
play an essential role in the survival of LSCs. The protein is
required for PIP2 extraction from the PM and its presentation
for PLCb3 to complete PIP2 hydrolysis, Ca
2+ release, and subse-
quent bioenergetics. Through this mechanism, ORP4L was
found to maintain the oxidative phosphorylation and survival of
LSCs. Meanwhile, we found that this process in LSCs may serve
as a target for the development of pharmaceuticals for leukemia
therapy.
Reprogramming of energy metabolism has been substanti-
ated as an emerging hallmark and therapeutic target in leukemia
(Hainaut and Plymoth, 2013; Hanahan and Weinberg, 2011).
However, its targeting in cancer cells is challenging, as the
healthy cells depend on the same pathways for energy supply
(Hainaut and Plymoth, 2013). ORP4L is expressed in T-ALL cells
and LSCs from AML patients but not in T cells or HSCs. We
selected AML-LSCs as a target for the investigation of the ther-
apeutic potential of ORP4L. ORP4L knockdown in the LSCs
resulted in defective bioenergetics and autophagic death of thecells; the specific inhibitor of ORP4L, LYZ-81, showed similar ef-
fects. LYZ-81 was capable of selectively eradicating engrafted
human LSCs from NOD/SCID recipient mice after ex vivo or
in vivo treatments. We therefore consider ORP4L to be a poten-
tial target of pharmaceuticals for leukemia therapy.
In general, the processes regulating IP3 generation are well
mapped and are known to play fundamental roles in a variety
of Ca2+-dependent cell signaling pathways. Our study offers
the extended insight into PLC catalysis that a cofactor is required
for PIP2 extraction from the PM and its presentation for PLC. Our
recent study (Zhong et al., 2016b) demonstrated that ORP4L in-
teracts with PLCb3 in T-ALL cells. Here, ORP4L is found to be
expressed selectively in LSCs but not in normal HSCs and to
play a critical role in LSCs bioenergetics. It forms a complex
with Gaq/11 and PLCb3 to control cytosolic and mitochondrial
parallel Ca2+ spike oscillations that sustain oxidative phosphor-
ylation. We found that ORP4L extracts PIP2 from the PM, while
PLCb3 is unable to do this. In living KG1-a and LSCs, ORP4L
knockdown resulted in the retention of PIP2 in the PM, which
could not be reversed by overexpressing PLCb3. Overexpres-
sion of wild-type ORP4L but not mutants deficient in PIP2 or
PLCb3 binding induced PIP2 hydrolysis by PLCb3. These find-
ings were supported by data from a cell-free reconstituted sys-
tem. The results indicated that the PIP2 extracted by ORP4L
could be delivered to its cognate PLCb3 via a physical interac-
tion of the two proteins.
Our MD simulations supported the notion that ORP4L accom-
modates PIP2 within its ORD. In the cell-free system, ORP4L
alone could extract PIP2 from the PM, and the addition of
PLCb3 allowed PIP2 hydrolysis, the reaction product DAG re-
maining in the PM. We thus envision that in living cells, the
PLC reaction does not involve complete extraction and accom-
modation of the PIP2 fatty acyl chainswithin theORP4LORD.We
hypothesize that the ORP4L interacts with themembrane-bound
PIP2 with the inositol-phosphate-binding cleft at themouth of the
ORD pocket, thereby pulling the PIP2 partly out of the membrane
for immediate hydrolysis by the PLCb3. The DAG produced
would thus remain in the PM.
To conclude, our data demonstrate that LYZ-81 selectively
eliminates LSCs in vitro and in vivo via the inhibition of ORP4L,
suggesting this compound as a starting point of drug develop-
ment for LSCs elimination in leukemia.STAR+METHODS
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Antibodies
Rabbit polyclonal anti-ORP4L Sigma-Aldrich Cat#HPA021514; RRID:AB_1854813
Rabbit polyclonal anti-Pyruvate Dehydrogenase
E1-alpha subunit [p Ser293]
Novus Cat# NB110-93479; RRID:AB_1237282
Rabbit polyclonal anti-Pyruvate Dehydrogenase Cell Signaling Cat#2784; RRID:AB_2162928
Rabbit monoclonal anti-AMPK-alpha, phospho
(Thr172) Clone 40H9
Cell Signaling Cat#2535; RRID:AB_331250
Rabbit polyclonal anti-LC3B Cell Signaling Cat#2775; RRID:AB_915950
Rabbit polyclonal anti-AMPK (23A3) Cell Signaling Cat# 2603; RRID:AB_10841287
Mouse monoclonal anti-ACTB Proteintech Group Cat# 60008-1-Ig; RRID:AB_2289225
Purified Anti-PtdIns (4,5)P2 IgM Echelon Biosciences Cat# Z-P045; RRID:AB_427225
Goat anti-pan-cadherin (C-19) Santa Cruz Cat# sc-1499; RRID:AB_630957
Mouse monoclonal anti-human Ki-67 antibody BioLegend Cat# 350526; RRID:AB_2562872
Alexa Fluor 647 mouse monoclonal anti-human
CD45 Antibody
BioLegend Cat# 304026; RRID:AB_893337
Secondary Antibody (Goat Anti-Rabbit Antibody
Conjugated to Horseradish Peroxidase)
Bio-Rad /AbD Serotec Cat# 166-2408EDU; RRID:AB_11125345
Secondary Antibody (Goat Anti-Mouse IgG
(H+L)-HRP Conjugate antibody)
Bio-Rad /AbD Serotec Cat# 170-6516; RRID:AB_11125547
Secondary Antibody (Rabbit Anti-Goat IgG
(H+L)-HRP Conjugate antibody)
Bio-Rad /AbD Serotec Cat# 172-1034; RRID:AB_11125144
Goat polyclonal anti-Rabbit IgG (H+L)
Cross-Adsorbed Secondary Antibody,
Alexa Fluor 546
Thermo Fisher Scientific Cat# A-11035; RRID:AB_143051
Donkey polyclonal anti-Goat IgG (H+L)
Cross-Adsorbed Secondary Antibody,
Alexa Fluor 647
Thermo Fisher Scientific Cat# A-21469; RRID:AB_2535872
Goat polyclonal anti-mouse IgG (H+L)
Cross-Adsorbed Secondary Antibody,
Alexa Fluor 488
Thermo Fisher Scientific Cat#A-11001; RRID:AB_2534069
Mouse monoclonal anti-Human CD38 Antibody,
FITC Conjugated
Miltenyi Biotec Cat# 130-092-259; RRID:AB_615091
Mouse monoclonal anti-Human CD34 Antibody,
PE Conjugated
Miltenyi Biotec Cat# 130-081-002; RRID:AB_244351
Bacterial and Virus Strains
E. coli DH5a Vazyme Biotech Cat#C502-02/03
E. coli BL21 (DE3) Vazyme Biotech Cat#C504-02/03
Lentivirus Shanghai GenePharma http://www.genepharma.com/En/
Biological Samples
Human AML bone marrow samples Department of Hematology, Guangdong








Normal umbilical cord (UCB) blood Department of Hematology, Guangdong
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Chemicals, Peptides, and Recombinant Proteins
TRIzol Regent Thermo Fisher Scientific Cat#15596026
RNase inhibitor TaKaRa Cat#2313A
Penicillin-Streptmycin Solution HyClone Cat# SV30010
Fetal bovine serum Collected In Australia Cat#JRFBS-04
Iscove’s Modified Dulbecco’s Medium (IMDM) GIBCO (life) Cat#12440-053
Methocult GF H4534 STEMCELL Technologies Cat#04534
Stem Span SFEM STEMCELL Technologies Cat#09600




Protease Inhibitor Cocktail Roche Group REF 11697498001
SDF-1 a R&D systems Cat#350-NS-050
Fluo-4 AM Thermo Fisher Scientific Cat#F14217
Rhod-2 AM Thermo Fisher Scientific Cat#R1244
3-MA Selleck Cat#S2767
Kaempferol Selleck Cat#S2314
Compound C EMD Chemicals Cat#171260-10MG
7-AAD Thermo Fisher Scientific Cat#A1310
OCT embedding medium Sakura Cat#4583
OSW-1 This paper N/A
LYZ-81 This paper N/A
Recombinant ORP4L protein This paper N/A
Recombinant OSBP protein This paper N/A
Recombinant PLCb3protein This paper N/A
Critical Commercial Assays
EasyScript First-Strand cDNA Synthesis SuperMix TransGen Biotech Cat# AE301-03
GoTaq qPCR Master Mix Promega Cat# A6002
Oxygen Consumption Rate Assay Kit Cayman Chemical Cat#600800
ATP Bioluminescence Assay Kit CLS II Roche Cat#11699695001
LIVE/DEAD Fixable Far Red Dead Cell Stain Kit Thermo Fisher Scientific Cat#L10120
HitHunter Inositol(1,4,5)-Trisphosphate Assay Kit DiscoverRx Tech Cat#90-0037
BD Fixation/Permeabilization kit BD Biosciences Cat#554714
Isolation of CD34+CD38 cells Kit Miltenyi Biotec Cat#130-056-701
Anti-FITC MicroBeads Miltenyi Biotec Cat#130-048-701
Nucleofector Kits for Human CD34+ cells Lonza Cat#VPA-1003
Bio-Rad (Hercules, CA) Dc Assay Bio-Rad Cat#500-0119
Experimental Models: Cell Lines
KG1-a cells ATCC TIB-152
Experimental Models: Organisms/Strains




The shRNA sequences used Table S3 N/A
Oligonucleotide primers used Table S3 N/A
Recombinant DNA
Recombinant cDNA constructs Table S3 N/A
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Software and Algorithms
FlowJo_V10 software FlowJo https://www.flowjo.com
ImageJ NIH public software https://imagej.nih.gov/ij/
Molecular Operating Environment (MOE), 2013.08 Chemical Computing Group http://www.chemcomp.comCONTACT FOR REAGENT AND RESOURCE SHARING
Further information and requests for resources and reagents should be directed to andwill be fulfilled by the LeadContact, Daoguang
Yan (tydg@jnu.edu.cn).
EXPERIMENTAL MODELS AND SUBJECT DETAILS
Human specimens and cell line
This study was approved by the institutional ethics committee of Jinan University and was performed in accordance with the Decla-
ration of Helsinki. Normal umbilical cord (UCB) blood and human AML bone marrow samples were obtained after obtaining written
informed consent at Guangdong General Hospital, Guangzhou and Department of Hematology, Chang Zheng Hospital, ShangHai.
The clinical information and the applications for which each sample was used are provided in Table S2. The AML and normal UCB
cells were isolated and processed as previously described (Guzman et al., 2001). The sampleswere collected and subjected to Ficoll-
Paque density gradient separation to isolate mononuclear cells, followed by CD34+CD38- cells isolation by using MACS enrichment
kit (Milltenyi Biotec, Auburn, CA) according to the manufacturer’s manual, within 12 h of collection. The purity of the enriched
CD34+CD38- cells was monitored by staining the cells with FITC conjugated anti-Human CD38 antibody (1:100; Miltenyi Biotec
Cat# 130-092-259) and PE conjugated anti-Human CD34 antibody (1:100; Miltenyi Biotec Cat# 130-081-002), and analyzed by
flow cytometry. The samples were cryopreserved in freezing medium consisting of Cryostor CS10 (BioLife Solutions, Bothell,
WA). Upon thawing, the cells were cultured in Serum-Free Medium (STEMCELL Technologies, Vancouver, BC, Canada) supple-
mented with 10 ng/mL rIL3 (PeproTech, Rocky Hill, NJ), 10 ng/mL rFlt3 (PeproTech, Rocky Hill, NJ), and 25 ng/mL rSCF (PeproTech,
Rocky Hill, NJ) at 37C in a humidified atmosphere containing 5% CO2. Leukemic stem-like CD34
+CD38- KG1-a cells were isolated
from KG1-a cells purchased from American Type Culture Collection by using MACS enrichment kit. This cell line was authenticated
by Promega short-tandem repeat analysis and tested for mycoplasma contamination before experiments. Cells were cultured in
IMDM supplemented with 10% FBS and 100 units/mL penicillin and 100 mg/mL streptomycin in a humidified atmosphere containing
5% CO2.
Validation of the stem cell status of the isolated LSCs
To characterize ORP4L in LSCs, we enriched CD34+CD38- LSCs with purity greater than 95% from AML patients, predominantly
representing quiescent G0 cells (Figure S7A). In vitro colony-forming unit (CFU) assays indicated that the isolated LSCs are able
to produce colonies after at least four re-plating (Figure S7B). Serial transplantation of LSCs from three individual AML specimens
(i.e., successful engraftment in bone marrow of NOD/SCID mice) was readily evident after the 1st transplantation (Figures S7C
and S7D). Injection of LSCs purified from the 1st engrafted mice resulted in successful engraftment in the 2nd recipients. The trans-
planted LSCs gave rise to CD34+CD38-, CD34- and CD34+CD38+ non-stem AML cells in the 1st and 2nd recipients, indicating the
long-term engraftment and differentiation capacity of our purified LSCs. Moreover, immunofluorescence staining of bone marrow
and spleen sections with anti-hCD34 showed infiltration of human AML cells in the transplant recipient mice (Figure S7E).
Animal studies
NOD/SCID mice were obtained from Nanjing Biomedical Research Institute of Nanjing University and kept under pathogen-free
conditions in the Laboratory Animal Center, Jinan University. All procedures were performed based on the UCLA Animal Research
Committee-approved protocols. 4 week-old female mice were sublethally irradiated with 11 rad/g by a 137Cs irradiator (Gammacell
3000 Elan, Best Theratronics, Kanata, ON, Canada) and used for transplantation within 24 h.
For experiments in Figure 1E, AML-CD34+ cells were infected with shNT and shORP4L lentivirus for 48 h, the infected cells with
GFP were sorted by flow cytometry; for experiments in Figure S3A, AML-CD34+ and UCB-CD34+ cells pre-incubated with 5 nM
LYZ-81 for 4 h. NOD/SCID mice were injected with 1 3 107 treated cells via the tail vein in a final volume of 0.2 mL of PBS with
0.5% FBS. Engraftment was assessed 8 weeks after transplantation by Alexa Fluor 647 conjugated anti-human CD45 antibody
(1:100; BioLegend Cat# 304026), FITC conjugated anti-Human CD38 antibody (1:100; Miltenyi Biotec Cat# 130-092-259) and PE
conjugated anti-Human CD34 antibody (1:100; Miltenyi Biotec Cat# 130-081-002) staining of bone marrow cells.e3 Cell Reports 26, 2166–2177.e1–e9, February 19, 2019
For in vivo therapy in Figures 3A and 13 107 AML-CD34+ cells were injected into irradiated NOD/SCIDmice via the tail vein in a final
volume of 0.2 mL of PBS with 0.5% FBS. After 6 weeks, the successful engraftment of human cells in peripheral blood was detected
by flow cytometry, and then these mice were randomly assigned into 2 groups, and treated for 7 weeks with PBS or LYZ-81 (5.8 mg/
kg/d, i.v.) (Tamura et al., 1997) each day. Disease evolution and effect of drugs on the HSC-enriched and LSC-enriched compart-
ments were determined after 7 weeks of treatment by flow cytometric analysis of human CD45+CD34+CD38- cells in bone marrow.
All of the animal experiments were repeated at least once.
For primary and serial xenogeneic transplantation of Figure S7C, 23 106 AML-CD34+CD38- cells from patients were injected into
NOD/SCID mice via the tail vein in a final volume of 0.2 mL of PBS with 0.5% FBS. 6 weeks after transplantation, primary recipient
mice were sacrificed, the engraftments were analyzed by staining of bone marrow cells. The bone marrow of primary recipient mice
were also collected, purified by using human CD34+CD38- cells MACS enrichment kit, then 23 106 human CD34+CD38- cells were
injected into irradiated secondary recipients via the tail vein. 6 weeks later, secondary recipient mice were sacrificed and the engraft-
ment of human bone marrow cells was analyzed by anti-human CD45, anti-human CD34 and anti-human CD38 staining.
METHOD DETAILS
Reagents and antibodies
Fluo4-AM, Rhod 2-AM, Alexa Fluor-488 goat anti-mouse IgG, Alexa Fluor-543 goat anti-rabbit IgG, Alexa Fluor-647 donkey anti-goat
IgG and TRIzol reagent were purchased from Invitrogen (Carlsbad, CA). Rabbit anti-ORP4L, 3-MA and PIP2 were from Sigma-Aldrich
(St. Louis, MO). SDF-1awas from R&D Systems (Minneapolis, MN). Compounds C was fromMerck Millipore (Billerica, MA). Kaemp-
ferol was purchased from Selleckchem. Alexa Fluor 647-anti-Ki67, Alexa Fluor 647-anti-human CD45, PE-anti-human CD34 and
FITC-anti-human CD38 were obtained from BioLegend (San Diego, CA). Anti-pan-cadherin was from Santa Cruz (Santa Cruz,
CA). Anti-PIP2 and BODIPY FL-PIP2 were from echelon-inc. Anti-p-PDH was obtained from Novus (St. Louis, MO); anti-LC3,
anti-p-AMPK, anti-PDH and anti-AMPK from Cell Signaling (Beverly, MA), and anti-actin from Proteintech Group (Chicago, IL).
Gene transfer
High-titer lentiviral stocks (above 109 TU/mL) carrying GFP-tag and shRNA-ORP4L, or ORP4L-cDNA were prepared by Shanghai
GenePharma Co (Shanghai, China). The shRNA sequence can be found in Table S3. For lentivirus infection, 1 3 106 cells were re-
suspended in 100 mL medium containing lentivirus (Multiplicity of infection, MOI = 100) and 5 mg/mL polybrene in 24-well culture
plates. Infections were carried out for 6 h at 37C, 5% CO2. After the end of infection, 400 mL medium was added. Knockdown or
overexpression was verified by western blotting after 4 and 2 days’ infection, respectively. For other gene transfers, cells were elec-
troporated using NucleofectorTM Kits for Human CD34+ cells and 4D-NucleofectorTM System (Lonza, Basel, Switzerland) according
to the manufacturer’s instructions. Functionality of cDNA overexpression by plasmid transfection was similarly verified by western
blotting. Primer sequences used for cDNA subcloning into vectors are provided in Table S3.
Quantitative real-time PCR
Total RNA was isolated with TRIzol reagent (Invitrogen) according to the manufacturer’s instructions. RNA samples were reverse
transcribed using random hexamer primers in the presence of RNase inhibitor (Takara Bio, Shiga, Japan). qRT-PCR was performed
with SYBR Premex EX Taq (Takara Bio) using the 7300 Sequence Detection System (Applied Biosystems, Foster City, CA). The data
was filtered as follows: if the cycle threshold (Ct) score for sample was ‘‘Undetermined,’’ or if the Ct score was > 35, the score was set
to 40 (McCall et al., 2014). A relative quantification analysis was performed using the DDCt method, with actin as endogenous refer-
ence. Relative gene expression is presented as log (2-DDCt). Primer sequences used are provided in Table S3.
PM preparations
PMwas prepared by using Plasma Membrane Protein Isolation and Cell Fractionation Kit (Invent Biotechnologies, Inc.) according to
the manufacturer’s instructions.
Lipidomics profiling by UPLC-HRMS
Freeze-dried cellular membrane samples were spiked with lipid internal standard solution (in methanol) containing lyso-phosphati-
dylcholine (LPC) 19:0, phosphatidylcholine (PC) (19:0/19:0), phosphatidylethanolamine (PE) (17:0/17:0), sphingomyelin (SM) (d18:1/
12:0), triacylglycerol (TAG) (15:0/15:0/15:0), ceramide (Cer) (d18:1/17:0), free fatty acid (FFA) 16:0-d3 and FFA 18:0-d3. The mixture
was vortexed for 1min followed by addition of 1mL of methyl tert-butyl ether and 15min shaking. Then 250 mL of water was added for
biphasic formation. The up-layer organic phase was collected and freeze-dried. The lipid residue was dissolved prior to analysis.
Cellular PM lipidomics profiling was performed in a Waters UPLC system coupled with a Q Exactive HF mass spectrometry
(Thermo Fisher Scientific, Rockford, IL, U.S.A.) Chromatographic separation of lipids was achieved in a BEH C8 column
(2.1 mm 3 100 mm, 1.7 mm, Waters, Milford, MA, U.S.A.). The elution solvents consisted of A (ACN: H2O = 60:40, v/v) and
B (IPA: ACN = 90:10, v/v), both contained 10 mM ammonium acetate. The elution composition started at 32% B for the initial
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2.4 min column flushing, the gradient was back to 32% B at 18.1 min, held for 1.9 min for column equilibration. The flow rate was
0.26 mL/min. The column temperature was set at 55C. The sample manager temperature was set at 12C.
Lipidomics data were acquired in both ESI positive and negative modes at scan ranges of 400 –1300 Da and 200 – 1800 Da,
respectively. The spray voltage was 3.5 kV for positive mode and 3.0 kV for negative mode. The capillary temperature maintained
at 300C. The Auxiliary gas heater temperature was at 350C. The flow rate of sheath gas and auxiliary gas was 45 arb and
10 arb, respectively. The S-lens RF level was 50. The AGC target and maximum IT were 3x106 ions capacity and 100 ms for full
MS scan, while were 1x105 ions capacity and 50 ms for MS/MS scan. Mass resolution was set to be 120,000 and 30,000 for full
scan MS andMS/MS. The TopN (N, the number of top most abundant ions for fragmentation) was set to 10. The normalized collision
energy (NCE) was set to be a combination of 25, 35 and 45 eV.
Lipid identities were assigned based on accurate masses, retention time and/or MS/MS fragments. All detected lipids were quan-
tified by normalization to the corresponding lipid internal standard. The lipid nomenclature follows the LIPIDMAPS classification and
nomenclature system.
Protein expression and purification
Open reading frames of cDNA were cloned into pGEX-4T-1 plasmid (Addgene, Cambridge, MA) and transformed into E. coli
RosettaTM (DE3) (Novagen), cultured at 37C to OD600 0.6-0.8, followed by induction with 0.5 mM IPTG for 16-18 h at 18C. The
Rosetta cells were collected and lyzed in cell lysis buffer (150 mM NaCl, 1% Triton X-100, 50 mM Tris-HCl, pH 8.0), containing
with 1 mM phenylmethylsulfonyl fluoride (PMSF). Next, the samples were sonicated in a mixture of ice water with the following set-
tings: (4 s on, 6 s off, 60% input, 4min), and centrifuged (10,000 x g for 20 min at 4C) to obtain the soluble protein extracts. Add
Glutathione Sepharose 4B beads (GE Healthcare) into the protein extracts according to the manufacturer’s protocols. Washed
the beads with cell lysis buffer and 50mMTris-HCl (pH 8.0) for 3 times, respectively. Finally, eluted the fusion protein with Glutathione
reduced elution buffer (20mMGlutathione reduced in 50mMTris-HCl pH 8.0) and dialyzed against PBS. The purified GST fusion pro-
teins were finally concentrated by Amicon Ultra-4 Centrifugal Filter Devices (Merck Millipore) and stored at 80C.
Measurement of the kinetics of PIP2 clearance
Cells seeded onto coverslips were incubated with 1 mMBODIPY FL-PIP2 (echelon-inc.com) for 10 min at room temperature in ECB
(130 mM NaCl, 5 mM KCl, 1.5 mM CaCl2, 1 mM MgCl2, 25 mM HEPES, pH 7.5, 1 mg/mL BSA, and 5 mM glucose). The BODIPY
FL-PIP2 images of cells were excited with low-intensity 488-nm laser excitation and acquired at 2 s intervals alternately under time-
lapse mode by confocal microscopy (Zeiss LSM 510 Meta). The baseline fluorescence was collected 20 s before the ligand stimu-
lation (500 ng/mL SDF-1a). Image data were subsequently analyzed using ImageJ (National Institutes of Health) and were presented
as a ratio of F/F0 in the final results, where F0 represents baseline fluorescence intensity in each cell.
PIP2 extraction assay
Cells were incubated with 1 mM PIP2 (Sigma-Aldrich) for 10 min at room temperature in ECB before used for PM preparation. The
assay mixture consisted of 50 mL of assay buffer (50 mM HEPES, pH 7.0, 100mM KCl, 6 mM MgCl2, 0.6 mM CaCl2, 2 mM EGTA)
(Lomasney et al., 1996), 5 mg of GST-tag proteins and 10 mg of PM. The assay mixture was incubated at 37C for 30 min. After
the reaction, centrifuged and collected the PM in pellet for analysis of remaining PIP2 by dot-blot. The suspension was incubated
with Glutathione Sepharose for 1h at room temperature to pull-down the proteins and their binding PIP2, centrifuged and collected
the pellet for analysis of remaining PIP2 by dot-blot (Figure 5I).
Reconstituted cell-free system
Cells were incubated with 1 mMPIP2 (Sigma-Aldrich) for 10 min at room temperature in ECB and used for PM preparation. The assay
mixture consisted of 50 mL of assay buffer (50mM HEPES, pH 7.0, 100 mM KCl, 6mM MgCl2, 0.6 mM CaCl2, 2 mM EGTA), 5 mg of
GST-tag proteins and 10 mg of PM. The assay mixture was incubated on ice for 10 min, the reaction was started by the addition of
GTPgS (50 mM) and incubation at 37C for 10min. After the reaction, centrifuged and collected the PM in pellet for analysis of remain-
ing PIP2 and DAG. The suspension was used for IP3 generation (Figure 6A).
Dot blots for PIP2 levels
The PIP2 of PMs was released by incubation of lysis buffer (50 mM Tris, pH 7.5, 300 mM NaCl, 5 mM EGTA, 20 mM DTT, 2% Triton
X-100 and 50 mM NaF) at 37C for 30 min. Dot blots were conducted as described (Li et al., 2014). Briefly, after centrifugation, 1 mL
of suspension was spotted onto nitrocellulose membrane (Bio-Rad Laboratories, Hercules, CA), probed with PIP2 antibody (1:500,
Echelon Biosciences) or PM internal loading control pan-cadherin antibody (Santa Cruz), and detected using a HRP-conjugated sec-
ondary antibody and enhanced chemiluminescence. Experiments were repeated at least three times.
Microscale thermophoresis
The protein concentration was diluted to 20 mM using the labeling buffer (50 mM HEPES with 150 mM NaCl, pH 8.0). Fluorescence
labeling of ORP4L was performed following with the protocol of NT647-NHS using lysine residues. 100 mL of 60 mMNT647-NHS dyee5 Cell Reports 26, 2166–2177.e1–e9, February 19, 2019
wasmixedwith ORP4L at a 1:1 ratio followed by incubation for 30min at room temperature in the dark. Unbound dyewas removed by
gel filtration on Sephadex G25 (GE Healthcare). The purity was monitored by measuring the ratio of protein to dye (spectroscopically
by measuring absorption at 280 nm for the protein and 650 nm for the dye) after the clean-up procedure.
The concentrations of compounds were remained at 1 mM in a binding buffer (50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 0.05%
Tween-20). After 30 min incubation, the samples were loaded into microscale thermophoresis (MST)-grade glass capillaries. The in-
tensities of the LED and laser were set at 40%. The MST analyses were performed using a Monolith NT.115 and the fitting curve was
obtained using NTA analysis 1.4.23 via Hill fitting, and the KD is the numeric equivalent of the concentration of LYZ-81 or PIP2 when
the response is half of the plateau response (Rmax).
IP3 and DAG measurement
IP3 was measured using the HitHunter IP3 Fluorescence Polarization Assay Kits (DiscoverRx Tech, Fremont, CA, USA) according to
the manufacturer’s instructions. For the DAGmeasurement, the PMs were disrupted by ultrasonication, after centrifugation, the sus-
pension was used for analysis by using (DAG/DG) ELISA Kit (J&L Biological, ShangHai, China) according to the manufacturer’s
instructions.
Surface plasmon resonance assay
SPR experiments were carried out using a ProteOn XPR36 SPR instrument (BioRad Hercules, CA). Immobilization of proteins was
performed using amine coupling to a General Layer Medium (GLM) (medium density) biosensor chip (BioRad). Standard amine
coupling was used to immobilize proteins (20 nM in 10 mM sodium acetate buffer, pH 4.5) to the EDAC/Sulfo-NHS activated surface
of a GLH biosensor chip (BioRad) at a density of 200-600 resonance units (RU) according to themanufacturer’s instructions. After the
injection of proteins, the surface was blocked with 1 M ethanolamine. The final immobilization level for proteins was approximately
12,000 RU. Compound was prepared in phosphate buffered saline, pH 7.4, containing 0.005%Tween-20 and injected at 100mL/min
for 250 s at concentrations of 10-0.625 mM (1:2 dilutions). Following compound injection, the chip surface was regenerated with 40 s
pulses of running buffer. The compound concentration data collected were reference-subtracted using Biacore Evaluation software.
Titrations were reference-subtracted using ProtedOn ManagerTM 2.0. Each titration was globally analyzed using the 1:1 Langmuir
binding model to obtain the kinetic rate constants (kon and koff). The equilibrium dissociation constant (KD) was calculated from the
rate constants. Global kinetic rate constants (ka and kd) were derived for each reaction, and the equilibrium dissociation constant, KD,
was calculated using the equation KD = kd / ka.
Molecular docking
A homology model of ORP4L was generated based on a crystal structure of Osh3 ORD from Saccharomyces cerevisiae (PDB entry
code: 4IC4) using Molecular Operating Environment (http://www.chemcomp.com) software. The sequences of these two models at
the binding pocket area are highly conserved. Hydrogen atoms were added to the protein using the MOEmodeling suite before car-
rying out the docking studies. Minimizing contacts for hydrogen, the structures were subjected to an Amber99 energy minimization
protocol. The structure of LYZ-81 was energy-minimized, the atomic partial charges were calculated with the MMFF94s force field,
and all possible ionization states were generated at pH 7.0. LYZ-81 was docked into the homologymodel usingMOE; the binding site
was modeled based on previous information on the sterol binding site (Im et al., 2005). The default Triangle Matcher was used as the
placement method followed by force field refinement, and London DG scoring was used for the docking. The top-ranked conforma-
tion of the compound was selected for the ligand-receptor binding mode analysis (Clark and Labute, 2007).
MD simulation
The coordinates of PIP2were obtained from the crystal structure of Osh3ORD in complexwith PI(4)P fromSaccharomyces cerevisiae
(PDB code: 4INQ). ORP4L/PIP2 complex was generated by superposing ORP4L and 4INQ. GPU-based (Götz et al., 2012; Salomon-
Ferrer et al., 2013) MD simulations were performed on the ORP4L/PIP2 complex and apo-ORP4L using the PMEMD module from
AMBER 12 (D.A. Case et al., 2012).
The partial atomic charges of IP3 were calculated through the Gaussian 09 (Frisch et al., 2009) program by using the Hartree-Fock
method with the 6-31G(d) basis set. The Antechamber program was then used for fitting the restricted electrostatic potential (RESP)
and assigning the GAFF force field parameters (Mukherjee et al., 2011). For the protein receptor ORP4L, the AMBER ff12SB force
field was used (Cornell et al., 1995; Hornak et al., 2006). The ligand-receptor complex was neutralized by adding sodium/chlorine
counter ions, and solvated in an octahedral box of TIP3P (Wang et al., 2006) water molecules with solvent layers 10 Å between
the box edges and solute surface. The SHAKE (Miyamoto and Kollman, 1992; Ryckaert et al., 1977) algorithm was used to restrict
all covalent bonds involving hydrogen atomswith a time step of 2 femtoseconds (fs). The Particle mesh Ewald (PME) method (Darden
et al., 1993) was performed to treat long-range electrostatic interactions.
Three steps of minimization were performed before the heating step. All atoms were restrained with 50 kcal/(mol,Å2), whereas the
solvent molecules were not restrained. This step included 2,000 cycles of steepest descent minimization and 2,000 cycles of con-
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included 2,500 cycles of steepest descent minimization and 2,500 cycles of conjugated gradient minimization. The third step
included 5,000 cycles of steepest descent minimization and 5,000 cycles of conjugated gradient minimization without restraint.
After the energy minimizations, the whole system was heated from 0 to 300 K in 50 picoseconds (ps) using Langevin dynamics at a
constant volume and then equilibrated for 400 ps at a constant pressure of 1 atm. A weak constraint of 10 kcal/ (mol,Å2) was used to
restrain all heavy atoms in the receptor-ligand complexes during the heating steps. Finally, periodic boundary dynamic simulations
were conducted on the whole system with an NPT (constant composition, pressure, and temperature) ensemble at a constant pres-
sure of 1 atm and 300 K in the production step. Each system was simulated for 100 ns. The coordinates of each system were saved
every 4 ps. The root-mean-square deviations (RMSDs) of ORP4L, pocket loop (residues 520-540), and IP3 were calculated. Clus-
tering was applied to detect populated conformations with pairwise RMSD of 1.5 Å (Ca only) as the cutoff.
Binding energy calculation






where Gepx is receptor-ligand complex energy, Gepx is unbound receptor energy, and Glig is ligand energy.
MM-PBSA (Molecular Mechanics-Possion-Boltzmann/Surface Area) calculates the binding free energy considering the desolva-
tion of the ligand and the unbound protein on the basis of a thermodynamic cycle. Equation (1) is also approximately calculated the
follows:
DGbinding =DEMM  TDS+DGsol (2)DEMM =DE
ele +DEndw (3)
where DEMM is the molecular mechanical energy obtained from the electrostatic (DEele) and the van der Waals (DEndw) interactions
within the system, is the solute entropic contribution at temperature T (kelvin) and the solvation free energy (DGsol) represents the






whereDeelsol is the polar contribution to solvation, andDG
nonpoular
sol is the nonpolar solvation term. The former component was calculated
using the PB calculation, whereas the latter term is determined using Equation (5):
DGnonpolarsol =gSASA+b (5)
where SASA is the solvent-accessible surface area (Å2) and g and b represent experimental solvation parameters.
Steered MD simulation
Three different snapshots of ORP4L/IP3 were taken from the MD simulation trajectories after the system reached stable. They were
subjected for 2 ns SMD simulations where the restraint is time-dependent as in:
VrestðtÞ= k½x  x0ðtÞ2
Where ðxÞ is the distance of the specified atoms. SMD simulations were performed under the NVT ensemble. The maximal pulling
distance was set to 10 Å between IP3 and the binding pocket of ORP4L (Asn 600). In order to avoid any distortions of the protein
due to pulling, the backbone of ORP4L was restrained with a force constant of 50 kcal/(mol,Å2). SMD simulations were repeated
3 times with different staring ORP4L/IP3 complexes. By integrating the force over distance, a generalized work can be computed.
Co-immunoprecipitation
CD34+CD38- KG1-a cells were washed twice with ice-cold PBS and incubated on ice for 30min with 1mL lysis buffer (50mMTris-Cl,
150 mM NaCl, 0.5 mM MgCl2, 10% glycerol, and 0.5% Triton X-100, pH 8.0) supplemented with Protease Inhibitor Cocktail (Roche
Group). Cell lysates were centrifuged for 10min at 12,000 x g. The supernatant was preabsorbed for 1 h at 4Cwith 50 mL of Protein G
agarose (Invitrogen). The recovered supernatant was incubated overnight with ORP4L (3 mg; Sigma-Aldrich Cat#HPA021514) anti-
body at 4C. 50 mL Protein G agarose was added to the lysate-antibody mixture and incubated at 4C on a roller for 2 h. Agarose
beads were washed four times with lysis buffer and boiled in 30 mL of SDS-PAGE loading buffer. Samples were resolved on 10%
SDS-polyacrylamide gels and subjected to western blot analysis.
Immunofluorescence microscopy
For immunofluorescence staining of cells, cells seeded onto coverslips were stimulated with or without 500 ng/mL SDF-1a for 3 min
and fixed with 4% paraformaldehyde for 30 min at room temperature, followed by permeabilization with 0.1% Triton X-100 for 5 min,e7 Cell Reports 26, 2166–2177.e1–e9, February 19, 2019
and blocked with 10% FBS for 30 min at room temperature. Cells were then incubated with primary antibodies in 5% FBS at 4C
overnight. After washing 3 times (10 min each) with PBS, cells were incubated with fluorophore-conjugated secondary antibody
at 37C for 30 min. The specimens were analyzed using a Zeiss (Oberkochen, Germany) LSM 510 Meta laser scanning confocal
microscope system. For immunofluorescence staining of tissue sections, the sections were blocked with 10% BSA/PBS after
microwave antigen retrieval and incubated for 2 h at room temperature with PE conjugated anti-Human CD34 antibody (1:50; Miltenyi
Biotec Cat# 130-081-002) diluted in 5% BSA. After washing 3 times (10 min each) with PBS, the sections were mounted in fluores-
cence mounting medium (Invitrogen), and analyzed by confocal microscopy (Zeiss LSM 510 Meta laser system).
Imaging of parallel [Ca2+]c and [Ca
2+]m oscillations
Cells (53 105 cells) were incubated with 2 mMRhod-2 AM (for [Ca2+]m measurement) for 60 min at 37
C in ECB. Then the cells were
washed and re-loaded with 1 mMFluo-4 AM (for [Ca2+]c measurement) for additional 30min at 37
C, followed by an additional 20 min
incubation at 37C to permit dye de-esterification. Then, cells were plated onto glass-bottomed dishes and the ECBwas replaced by
IMDMwith 10% FBS. The [Ca2+]c and [Ca
2+]m images of cells were excited with low-intensity 488-nm laser excitation (for Fluo-4 AM)
and 516-nm laser excitation (for Rhod-2 AM) and acquired at 2 s intervals alternately under time-lapse mode by confocal microscopy
(Zeiss LSM 510 Meta). Image data were subsequently analyzed using ImageJ (National Institutes of Health) and were presented as a
ratio of F/F0 in the final results, where F0 represents baseline fluorescence intensity in each cell.
Extracellular flux assays and ATP measurements
Oxygen consumption was assessed using Oxygen Consumption Rate Assay Kit (MitoXpress-Xtra-HS Method; Cayman Chemical,
Ann Arbor, MI), a porphyrin-based phosphorescent oxygen-sensitive probe. Prior to assay, cells were transferred into fresh culture
medium containing 1% FBS. 10 mL of probe was added and the cells equilibrated at 37C. The assay was read using a Microplate
Reader (Synergy 4 Hybrid, BioTek, Winooski, VT). The maximal rate of oxygen consumption is proportional to the change in probe
fluorescence during the linear phase of the assay. Cellular ATP levels were determined by ATP Bioluminescence Assay Kit CLS II
(Roche, Basel, Switzerland) according to the manufacturer’s instructions.
Cell cycle analysis
For evaluation of cell cycle profile, cells were fixed by the BD Fixation/Permeabilization kit (554714, BD Biosciences, San Jose, CA)
according to the manufacturer’s instructions, stained with Alexa Fluor 647-anti-Ki67 (1:100; BioLegend Cat# 350526) for 45 min at
4C and re-suspended overnight at 4C in 0.5 mL of 5 mg/mL 7-AAD staining solution (Thermo Fisher Scientific). Cells were analyzed
by using flow cytometer (FACSAriaTM, BD) and the data were analyzed with the FlowJo_V10 software.
Cell death assay
Cell death was analyzed with the LIVE/DEAD Fixable Far Red Dead Cell Stain Kit (Thermo Fisher, Waltham, MA) according to the
manufacturer’s instructions. Briefly, cells werewashed oncewith PBS, and then incubatedwith LIVE/DEAD Fixable DeadCell Stain in
PBS for 30 min at room temperature in the dark. After washing with PBS with 1% FBS, cells were resuspended in PBS with 1% FBS
and run on the flow cytometer (FACSAriaTM, BD) and the data were analyzed by FlowJo_V10 software.
In vitro colony forming assay
Cells were plated at 13 103 cells/plate in Methocult GF H4534 as described (Guzman et al., 2005). Plates were incubated at 37C in
a humidified atmosphere at 5% CO2 and colonies were scored after 14 days of culture. Representative images from independent
biological samples were shown in the figures.
Hematoxylin and eosin staining
Tissues were fixed and embedded in OCT embedding medium and sliced by frozen slicer (Leica CM1850, Wetzlar, Germany). The
sections were stained with hematoxylin and eosin by using a standard protocol. Then, the stained sections were washed in 70%
ethanol and imaged with industrial digital camera TOUPCAMTM (Hangzhou, China).
Western blot analysis
Cells were suspended in lysis buffer (50mMTris–Cl, pH8.0, 150mMNaCl, 0.5mMMgCl2, 10%glycerol, 1%Triton X-100, 0.1%SDS)
with protease inhibitor cocktail (Roche Diagnostics) on ice for 10 min. Samples were centrifuged for 10 min at 12,000 3 g. The su-
pernatants were collected and protein concentrations were measured by the BioRad (Hercules, CA) Dc Assay. Protein extracts were
run on a 10% or 12% SDS polyacrylamide gel before transfer to a polyvinylidene difluoride membrane. Membranes were blocked
with 5% milk for 1 h and incubated with primary antibodies overnight, followed by incubation with the secondary antibodies for
1 h at room temperature. Primary antibodies used in this study were: anti-ORP4L (1:1000; Sigma-Aldrich Cat#HPA021514),
anti-Pyruvate Dehydrogenase E1-alpha subunit [p-Ser293] (1:1000; Novus Cat# NB110-93479), anti-Pyruvate Dehydrogenase
(1:1000; Cell Signaling Technology Cat#2784), anti-ACTB (1:3000; Proteintech Group, Cat# 60008-1-Ig), anti-AMPK-alpha, phosphoCell Reports 26, 2166–2177.e1–e9, February 19, 2019 e8
(Thr172) (1:1000; Cell Signaling Technology Cat#2535), anti-AMPK (1:1000; Cell Signaling Technology Cat# 2603), anti-LC3B
(1:1000; Cell Signaling Technology Cat#2775). The detection was carried out by enhanced chemiluminescence (Thermo Fisher
Scientific).
QUANTIFICATION AND STATISTICAL ANALYSIS
All data is presented as mean ± SD. The value of n is mentioned in the figure legends and always stands for separate biological rep-
licates. All in vitro experiments were repeated at least twice, and in vivo experiments were repeated at least once. All comparisons
between groups were made by unpaired two-tailed Student’s t test. Differences with * p < 0.05, **p < 0.01, and ***p < 0.001 were
considered statistically significant. n.s., not significant.e9 Cell Reports 26, 2166–2177.e1–e9, February 19, 2019
